Navamedic ASA

NAVA

NO0010205966

Pharmaceuticals

Market Closed - Oslo Bors Other stock markets 10:45:00 2024-06-14 am EDT			5-day change	1st Jan Change
34.3 ^NOK	+1.78%		+0.88%	-6.54%

May. 16	Navamedic ASA Receives Confirmation of an Extension of Its Contract with the Norwegian Hospital Procurement Trust for Continued Delivery of Antibodies to Norwegian Hospitals	CI
May. 06	Navamedic Rolls Out Erectile Dysfunction Drug in Sweden	MT

Navamedic ASA: Notice of Annual General Meeting

May 14, 2024 at 08:11 am EDT

The annual general meeting of Navamedic ASA (OSE: NAVA) will be held on Tuesday, June 4th 2024 at 09:00 (CET) in the Navamedic offices in Henrik Ibsens gate 100, 0255 Oslo. The Notice of the Annual General Meeting is attached. The Notice is posted electronically or by mail to all shareholders and is available on the company's website https://navamedic.com/investors/general-meeting/.

For further information, please contact:

Kathrine G. Andreassen, CEO, Navamedic, Mobile: +47 951 78 680 E-mail: kathrine@navamedic.com

Lars Hjarrand, CFO, Navamedic, Mobile: +47 917 62 842 E-mail: lars.hjarrand@navamedic.com

https://news.cision.com/navamedic-asa/r/navamedic-asa--notice-of-annual-general-meeting,c3979494

https://mb.cision.com/Main/17619/3979494/2796195.pdf

Latest news about Navamedic ASA

Navamedic ASA Receives Confirmation of an Extension of Its Contract with the Norwegian Hospital Procurement Trust for Continued Delivery of Antibodies to Norwegian Hospitals	May. 16	CI
Navamedic Rolls Out Erectile Dysfunction Drug in Sweden	May. 06	MT
Navamedic ASA Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 30	CI
Ingerø Reiten Investment Divests Navamedic Stake in NOK95 Million Deal	Mar. 13	MT
An unknown buyer acquired unknown minority stake in Navamedic ASA (OB:NAVA) from Ingerø Reiten Investment Company As for NOK 95 million.	Mar. 11	CI
Navamedic ASA Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 15	CI
Navamedic Acquires Rights to Distribute Erectile Dysfunction Treatment in Nordic Countries	Feb. 12	MT
Navamedic ASA Acquires Rights to Market and Distribute Eroxon in the Nordic Countries	Feb. 12	CI
Navamedic ASA Renews Contract Signed with Vitaflo International Limited	Dec. 21	CI
Navamedic Enters Agreement with Orion for Distribution of Parkinson's Drug Across Europe	Dec. 14	MT
Navamedic ASA and Orion Corporation Sign Non-Binding Term Sheet for Flexilev® in Europe	Dec. 13	CI
Navamedic ASA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 01	CI
Navamedic ASA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Navamedic ASA Elects Åsa Kornfeld as Members of its Board of Directors	23-05-31	CI
Navamedic Secures Ownership of Sweden’s Sensidose	23-05-26	MT
Navamedic ASA (OB:NAVA) completed the acquisition of Sensidose AB.	23-05-24	CI
EQL Pharma Closes Sensidose Bid, to Accept Navamedic Offer	23-05-17	MT
Navamedic ASA Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Norway's Navamedic Lifts Offer for Remaining Sensidose Shares	23-05-10	MT
Sweden’s EQL Pharma Increases Bid for Sensidose	23-04-24	MT
Navamedic Raises Takeover Offer for Sensidose, Agrees to Buy 57% Stake	23-04-24	MT
Navamedic Offers to Buy Sensidose for SEK75 Million	23-03-29	MT
Navamedic ASA (OB:NAVA) made an offer to acquire Sensidose AB for SEK 96 million.	23-03-28	CI
Navamedic ASA Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-16	CI
Navamedic ASA Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-16	CI

Chart Navamedic ASA

Duration

Period

More charts

Company Profile

Navamedic ASA is a Norway-based pharmaceutical company. It is a supplier of products delivered to hospitals and pharmacies. Navamedicâs product portfolio consists of prescription and Over The Counter (OTC) pharmaceuticals as well as other healthcare products registered as medical nutrition, medical devices, food supplements or cosmetics. The Companyâs offering is divided into four product areas: Consumer Health, Specialty Pharma, Medical Nutrition and Branded Generics. The Company has one business segment which is the Pharma division. Navamedic ASA is present in all Nordic countries, the Baltics and Benelux. The Company has two subsidiaries, Navamedic AB, through which the Company distributes more than 40 products and a Norway-based Novicus Pharma AS.

Sector

Pharmaceuticals

Calendar

2024-08-15 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Navamedic ASA

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

34.3 NOK

Average target price

46.5 NOK

Spread / Average Target

+35.57%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NAVAMEDIC ASA	-6.54%	55.94M
ELI LILLY AND COMPANY	+50.70%	791B
NOVO NORDISK A/S	+41.96%	630B
JOHNSON & JOHNSON	-7.15%	350B
MERCK & CO., INC.	+18.77%	328B
ABBVIE INC.	+8.79%	298B
ASTRAZENECA PLC	+18.02%	246B
ROCHE HOLDING AG	+1.27%	225B
NOVARTIS AG	+11.95%	218B
AMGEN INC.	+3.68%	160B

Other Pharmaceuticals

Navamedic ASA

Equities

NAVA

NO0010205966

Pharmaceuticals

Navamedic ASA: Notice of Annual General Meeting

EPS Revisions